The US FDA and Eli Lilly & Co. offered contrasting views on the utility of an emerging endpoint, progression-free survival 2, at the recent advisory committee review of Cyramza (ramucirumab) for first-line lung cancer.
Lilly described PFS2 as a useful, intermediate endpoint between progression-free survival and overall survival. In the case of the RELAY...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?